Villafane G, et al. - The efficacy and safety of high doses of transdermal nicotine on motor symptoms in Parkinson's disease (PD) were assessed in this study. Although this study failed to demonstrate significant improvement in UPDRS motor scores, high doses of transdermal nicotine were tolerated. Improvement in unblinded secondary outcomes (UPDRS-II, UPDRS-IV, doses of L-dopa-equivalents) proposed a possible benefit for patients treated with nicotine, which needed to be confirmed in larger double-blind, placebo-controlled studies.